Next Article in Journal
One Pot Synthesis of Large Gold Nanoparticles with Triple Functional Ferrocene Ligands
Previous Article in Journal
The Presence of Colony-Stimulating Factor-1 and Its Receptor in Different Cells of the Testis; It Involved in the Development of Spermatogenesis In Vitro
Open AccessReview

Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review

1
Nephrology Department, Bellvitge University Hospital, Hospitalet de Llobregat, 08907 Barcelona, Spain
2
IDIBELL Biomedical Research Institute, Hospitalet de Llobregat, 08907 Barcelona, Spain
3
Clinical Science Department, Campus de Bellvitge, Barcelona University, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
4
Pathology Department, Bellvitge University Hospital, Hospitalet de Llobregat, 08907 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Amandeep Bajwa
Int. J. Mol. Sci. 2021, 22(5), 2326; https://doi.org/10.3390/ijms22052326
Received: 28 January 2021 / Revised: 12 February 2021 / Accepted: 22 February 2021 / Published: 26 February 2021
(This article belongs to the Special Issue Pathobiology of Acute Kidney Injury)
Acute kidney injury in patients who suffer a malignancy is a common complication. Due to its high prevalence and effective treatment, one of the most frequent causes that both oncologists and nephrologists must be aware of is acute tubulointerstitial nephritis (ATIN). ATIN is an immunomediated condition and the hallmark of the disease, with the presence of a tubulointerstitial inflammatory infiltrate in the renal parenchyma. This infiltrate is composed mainly of T lymphocytes that can be accompanied by macrophages, neutrophils, or eosinophils among other cells. One of the major causes is drug-related ATIN, and some antineoplastic treatments have been related to this condition. Worthy of note are the novel immunotherapy treatments aimed at enhancing natural immunity in order to defeat cancer cells. In the context of the immunosuppression status affecting ATIN patients, some pathogen antigens can trigger the development of the disease. Finally, hematological malignancies can also manifest in the kidney leading to ATIN, even at the debut of the disease. In this review, we aim to comprehensively examine differential diagnosis of ATIN in the setting of a neoplastic patient. View Full-Text
Keywords: acute tubulointerstitial nephritis; onconephrology; acute kidney injury acute tubulointerstitial nephritis; onconephrology; acute kidney injury
Show Figures

Figure 1

MDPI and ACS Style

Martínez-Valenzuela, L.; Draibe, J.; Fulladosa, X.; Gomà, M.; Gómez, F.; Antón, P.; Cruzado, J.M.; Torras, J. Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review. Int. J. Mol. Sci. 2021, 22, 2326. https://doi.org/10.3390/ijms22052326

AMA Style

Martínez-Valenzuela L, Draibe J, Fulladosa X, Gomà M, Gómez F, Antón P, Cruzado JM, Torras J. Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review. International Journal of Molecular Sciences. 2021; 22(5):2326. https://doi.org/10.3390/ijms22052326

Chicago/Turabian Style

Martínez-Valenzuela, Laura; Draibe, Juliana; Fulladosa, Xavier; Gomà, Montserrat; Gómez, Francisco; Antón, Paula; Cruzado, Josep M.; Torras, Joan. 2021. "Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review" Int. J. Mol. Sci. 22, no. 5: 2326. https://doi.org/10.3390/ijms22052326

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop